PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17485025-9 2007 In adipose tissue, TAK-536 and candesartan reduced TNF-alpha expression but increased the expression of adiponectin, PPARgamma, C/EBalpha, and aP2. candesartan 31-42 peroxisome proliferator activated receptor gamma Mus musculus 117-126 26115674-9 2015 The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARgamma, encoded by PPARG) antagonist T0070907, showing the importance of PPARgamma activation for the neurorestorative effect of these sartans. candesartan 32-43 peroxisome proliferator activated receptor gamma Mus musculus 110-158 26115674-9 2015 The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARgamma, encoded by PPARG) antagonist T0070907, showing the importance of PPARgamma activation for the neurorestorative effect of these sartans. candesartan 32-43 peroxisome proliferator activated receptor gamma Mus musculus 160-169 26115674-9 2015 The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARgamma, encoded by PPARG) antagonist T0070907, showing the importance of PPARgamma activation for the neurorestorative effect of these sartans. candesartan 32-43 peroxisome proliferator activated receptor gamma Mus musculus 182-187 26115674-9 2015 The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARgamma, encoded by PPARG) antagonist T0070907, showing the importance of PPARgamma activation for the neurorestorative effect of these sartans. candesartan 32-43 peroxisome proliferator activated receptor gamma Mus musculus 236-245 22892395-9 2012 Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan. candesartan 148-159 peroxisome proliferator activated receptor gamma Mus musculus 20-68 22892395-9 2012 Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan. candesartan 148-159 peroxisome proliferator activated receptor gamma Mus musculus 70-79 22892395-9 2012 Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan. candesartan 148-159 peroxisome proliferator activated receptor gamma Mus musculus 187-196 22892395-9 2012 Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan. candesartan 274-285 peroxisome proliferator activated receptor gamma Mus musculus 20-68 22892395-9 2012 Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan. candesartan 274-285 peroxisome proliferator activated receptor gamma Mus musculus 70-79 22892395-9 2012 Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPARgamma activation may contribute to part or to all of the neuroprotective effect of candesartan. candesartan 274-285 peroxisome proliferator activated receptor gamma Mus musculus 187-196 22892395-0 2012 Candesartan, an angiotensin II AT1-receptor blocker and PPAR-gamma agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. candesartan 0-11 peroxisome proliferator activated receptor gamma Mus musculus 56-66